Tempus AI, Inc. $TEM Shares Sold by Sigma Planning Corp

Sigma Planning Corp trimmed its position in Tempus AI, Inc. (NASDAQ:TEM) by 82.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,129 shares of the company’s stock after selling 19,302 shares during the period. Sigma Planning Corp’s holdings in Tempus AI were worth $244,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the 3rd quarter valued at approximately $26,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI in the third quarter worth approximately $38,000. Tsfg LLC grew its position in Tempus AI by 1,515.2% in the third quarter. Tsfg LLC now owns 533 shares of the company’s stock worth $43,000 after acquiring an additional 500 shares during the period. Cloud Capital Management LLC acquired a new stake in Tempus AI during the third quarter worth $44,000. Finally, Danske Bank A S acquired a new stake in Tempus AI during the third quarter worth $48,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Insider Activity

In related news, CFO James William Rogers sold 10,084 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $595,460.20. Following the completion of the transaction, the chief financial officer directly owned 101,166 shares in the company, valued at $5,973,852.30. This trade represents a 9.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $51.13, for a total value of $8,500,362.50. Following the completion of the transaction, the chief executive officer directly owned 8,841,783 shares of the company’s stock, valued at approximately $452,080,364.79. This represents a 1.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 563,471 shares of company stock worth $29,837,342 in the last quarter. Insiders own 24.26% of the company’s stock.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG Research lowered its price target on Tempus AI but kept a Buy rating, signaling continued confidence in the stock’s long-term upside despite near-term valuation pressure. BTIG lowers Tempus AI price target but keeps Buy rating
• Positive Sentiment: Several recent writeups highlighted Tempus AI’s growing role in precision medicine, its AI-powered diagnostics platform, and its data licensing partnerships with biopharma, which support the bull case for long-term revenue growth and margin expansion. Seeking Alpha article on Tempus AI precision medicine demand
• Positive Sentiment: Coverage also pointed to Tempus AI’s earnings-call theme of improving growth and profitability, reinforcing expectations that recent operating momentum may continue. Tempus AI earnings call highlights growth and profitability
• Neutral Sentiment: Tempus AI announced a $400 million upsized offering of 0.00% convertible senior notes due 2032 and separately outlined a proposed $350 million convertible note sale, moves that may help reduce interest expense and optimize capital structure, but could also add dilution concerns. Tempus announces pricing of upsized convertible senior notes offering
• Neutral Sentiment: Additional headlines about expanding convertible note offerings and broader AI stock interest from Cathie Wood are drawing attention, but these items are more about market sentiment than a direct fundamental catalyst for TEM. Tempus AI and Scorpio Tankers expand convertible note offerings

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TEM shares. Mizuho began coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price target on the stock. Guggenheim cut their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, March 30th. BTIG Research reduced their price objective on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus set a $60.00 target price on shares of Tempus AI in a research note on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and a consensus target price of $70.86.

Tempus AI Stock Up 0.8%

Shares of NASDAQ TEM opened at $49.86 on Friday. The company has a quick ratio of 3.00, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The business’s 50 day moving average is $50.32 and its two-hundred day moving average is $62.37. Tempus AI, Inc. has a 52-week low of $41.73 and a 52-week high of $104.32. The firm has a market cap of $8.91 billion, a price-to-earnings ratio of -28.99 and a beta of 3.99.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. During the same period last year, the business posted ($0.24) earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. Research analysts predict that Tempus AI, Inc. will post -1.39 EPS for the current year.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.